X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
anastrozole (898) 898
humans (784) 784
female (736) 736
breast neoplasms - drug therapy (644) 644
breast cancer (584) 584
tamoxifen (580) 580
oncology (577) 577
postmenopausal women (566) 566
index medicus (523) 523
middle aged (384) 384
letrozole (380) 380
aromatase inhibitors (361) 361
aged (324) 324
antineoplastic agents, hormonal - therapeutic use (289) 289
randomized-trial (271) 271
postmenopause (266) 266
aromatase inhibitors - therapeutic use (261) 261
endocrine therapy (256) 256
cancer (233) 233
nitriles - therapeutic use (233) 233
exemestane (232) 232
triazoles - therapeutic use (232) 232
breast neoplasms - pathology (228) 228
treatment outcome (220) 220
aromatase inhibitors - adverse effects (218) 218
tamoxifen - therapeutic use (215) 215
aromatase inhibitor (197) 197
care and treatment (195) 195
adult (191) 191
chemotherapy, adjuvant (184) 184
antineoplastic agents, hormonal - adverse effects (182) 182
nitriles - adverse effects (172) 172
triazoles - adverse effects (169) 169
aged, 80 and over (163) 163
estrogen (156) 156
medicine & public health (154) 154
double-blind (150) 150
therapy (147) 147
women (136) 136
first-line therapy (131) 131
drug therapy (124) 124
adjuvant treatment (122) 122
chemotherapy (116) 116
fulvestrant (116) 116
analysis (113) 113
obstetrics & gynecology (111) 111
research (111) 111
nitriles - administration & dosage (110) 110
triazoles - administration & dosage (109) 109
health aspects (108) 108
trial (106) 106
disease-free survival (105) 105
pharmacology & pharmacy (104) 104
randomized controlled trials as topic (104) 104
phase-iii (103) 103
antineoplastic agents, hormonal - administration & dosage (101) 101
clinical trials (101) 101
tamoxifen - adverse effects (100) 100
aromatase inhibitors - administration & dosage (99) 99
hematology, oncology and palliative medicine (97) 97
megestrol-acetate (93) 93
tamoxifen therapy (93) 93
estradiol - analogs & derivatives (89) 89
antineoplastic combined chemotherapy protocols - therapeutic use (86) 86
breast neoplasms - metabolism (86) 86
risk factors (85) 85
breast neoplasms - mortality (84) 84
tamoxifen - administration & dosage (82) 82
combination (81) 81
neoplasm staging (81) 81
antineoplastic agents - therapeutic use (80) 80
aromatase (80) 80
prevention (76) 76
androstadienes - therapeutic use (73) 73
menopause (73) 73
clinical trials as topic (71) 71
neoplasms, hormone-dependent - drug therapy (71) 71
receptors, estrogen - metabolism (70) 70
metastasis (68) 68
efficacy (66) 66
adjuvant therapy (65) 65
male (65) 65
quality of life (65) 65
bone-mineral density (61) 61
double-blind method (61) 61
osteoporosis (61) 61
breast neoplasms - surgery (60) 60
endocrinology & metabolism (60) 60
follow-up studies (60) 60
survival (60) 60
drug administration schedule (59) 59
estradiol - therapeutic use (59) 59
bone density - drug effects (58) 58
retrospective studies (58) 58
internal medicine (56) 56
antineoplastic agents (55) 55
neoplasm metastasis (55) 55
prognosis (55) 55
cancer patients (54) 54
hormones (53) 53
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Annals of Oncology, ISSN 0923-7534, 2013, Volume 24, Issue 2, pp. 398 - 405
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2012, Volume 367, Issue 5, pp. 435 - 444
The combination of anastrozole and fulvestrant — which interfere with estrogen signaling by distinct mechanisms — increases progression-free and overall... 
PHASE-III TRIAL | MEDICINE, GENERAL & INTERNAL | ONCOLOGY-GROUP | TAMOXIFEN | DOUBLE-BLIND | RANDOMIZED-TRIAL | ENDOCRINE THERAPY | POSTMENOPAUSAL WOMEN | 1ST-LINE THERAPY | HORMONAL-THERAPY | FIRST-LINE THERAPY | Triazoles - administration & dosage | Triazoles - adverse effects | Estradiol - analogs & derivatives | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Nitriles - administration & dosage | Aromatase Inhibitors - adverse effects | Neoplasm Metastasis | Aged, 80 and over | Estradiol - adverse effects | Postmenopause | Adult | Female | Aromatase Inhibitors - administration & dosage | Estradiol - administration & dosage | Kaplan-Meier Estimate | Breast Neoplasms - drug therapy | Cross-Over Studies | Disease-Free Survival | Estrogen Antagonists - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Estrogen Antagonists - adverse effects | Breast Neoplasms - mortality | Aged | Nitriles - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Patient outcomes | Breast cancer | Dosage and administration | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Fulvestrant | Statistical analysis | Anastrozole | Estrogen receptors | Tamoxifen | Cancer therapies | Survival | Patients | Post-menopause | Metastases | Chemotherapy | Womens health | Aromatase | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 02/2007, Volume 25, Issue 5, pp. 486 - 492
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2012, Volume 366, Issue 6, pp. 520 - 529
Resistance to hormone therapy through activation of cellular pathways involving mTOR can develop in postmenopausal hormone-receptor–positive breast cancer.... 
TRIAL | WOMEN | MEDICINE, GENERAL & INTERNAL | EFFICACY | TAMOXIFEN | PHASE-III | LETROZOLE | SUPERIOR | AROMATASE INHIBITORS | FIRST-LINE THERAPY | ANASTROZOLE | Recurrence | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Bone Neoplasms - secondary | TOR Serine-Threonine Kinases - antagonists & inhibitors | Aromatase Inhibitors - adverse effects | Breast Neoplasms - chemistry | Aged, 80 and over | Postmenopause | Adult | Female | Aromatase Inhibitors - therapeutic use | Everolimus | Sirolimus - adverse effects | Sirolimus - analogs & derivatives | Sirolimus - therapeutic use | Kaplan-Meier Estimate | Receptor, Epidermal Growth Factor - analysis | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Stomatitis - chemically induced | Aged | Androstadienes - therapeutic use | Androstadienes - adverse effects | Drugs | Care and treatment | Usage | Hormone therapy | Patient outcomes | Drug utilization | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | TOR protein | Anastrozole | Endocrine therapy | Fatigue | Intracellular signalling | Rapamycin | Tamoxifen | Cancer therapies | Survival | Post-menopause | Fulvestrant | Signal transduction | Stomatitis | Hyperglycemia | Chemotherapy | Pneumonitis | Dyspnea | Aromatase | Antitumor activity | Respiration
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 08/2009, Volume 361, Issue 8, pp. 766 - 776
This study of adjuvant hormonal therapy in postmenopausal women with hormone-receptor–positive early breast cancer showed that disease-free survival was... 
SURVIVAL | MEDICINE, GENERAL & INTERNAL | EXEMESTANE | CONTINUED TAMOXIFEN | ADJUVANT ENDOCRINE THERAPY | RANDOMIZED-TRIAL | POSTMENOPAUSAL WOMEN | AROMATASE INHIBITORS | ANASTROZOLE | Aromatase Inhibitors - administration & dosage | Triazoles - administration & dosage | Triazoles - adverse effects | Double-Blind Method | Drug Administration Schedule | Follow-Up Studies | Neoplasm Recurrence, Local - prevention & control | Antineoplastic Agents, Hormonal - administration & dosage | Humans | Kaplan-Meier Estimate | Proportional Hazards Models | Fractures, Bone - epidemiology | Breast Neoplasms - drug therapy | Tamoxifen - administration & dosage | Incidence | Nitriles - administration & dosage | Antineoplastic Agents, Hormonal - adverse effects | Disease-Free Survival | Aromatase Inhibitors - adverse effects | Postmenopause | Female | Chemotherapy, Adjuvant | Tamoxifen - adverse effects | Nitriles - adverse effects | Women | Care and treatment | Usage | Breast cancer | Tamoxifen | Comparative analysis | Health aspects | Drug therapy | Womens health | Cancer therapies | Index Medicus | Abridged Index Medicus | Hormonal | Breast Neoplasms | epidemiology | administration & dosage | Triazoles | Nitriles | Adjuvant | drug therapy | Antineoplastic Agents | Local | prevention & control | Aromatase Inhibitors | Chemotherapy | Fractures | adverse effects | Bone | Neoplasm Recurrence | Cancer and Oncology | Kaplan-Meiers Estimate | Cancer och onkologi
Journal Article
Nigerian Journal of Physiological Sciences, ISSN 0794-859X, 2017, Volume 32, Issue 2, pp. 219 - 225
Although anastrozole (Anas) plays a key role in the management of endocrine sensitive post-menopausal (PM) breast cancer (BC), there is much variability in its... 
Postmenopausal | Breast cancer | Anastrozole | Estradiol
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 07/2014, Volume 371, Issue 2, pp. 119 - 129
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 11/2010, Volume 28, Issue 31, pp. 4674 - 4682
Journal Article
The Lancet, ISSN 0140-6736, 06/2002, Volume 359, Issue 9324, pp. 2131 - 2139
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 12/2005, Volume 353, Issue 26, pp. 2747 - 2757